Singapore: OHK Medical Devices, manufacturer of the HemaClear, single-use, sterile exsanguinating tourniquet device, announced that it has entered an exclusive agreement with Japan Medicalnext, a Mitsubishi Corporation company, for the distribution of HemaClear in Japan. OHK and Japan Medicalnext, will formally launch their entry into the Japanese market over the coming months.

The Japanese orthopedic devices market, estimated at $1.40 billion and growing at an annual rate of about 5 percent, represents one the largest markets in the world. "We are very excited to enter one of the largest global markets with such a well respected partner," said Mr Omer Inbar, CEO, OHK Medical Devices. Mr Inbar added, "The introduction of HemaClear in Japan is an important step in further establishing HemaClear as a standard of care in the APAC market following our recent launch of HemaClear in South Korea, Australia, and Thailand."

"We are very excited to launch this new tourniquet technology in the Japanese market," said Mr Takeru Fujihashi, vice president of Orthopedic Division, Japan Medicalnext. "The technology will lead a major change in the current procedure and will create new benefits to the market," added Mr Fujihashi.

Hemaclear will be represented by the orthopedic implant division of Japan Medicalnext, which includes 50 sales representative selling both external and internal fixation technologies.